MS4A1 and type 1 diabetes mellitus: The status of TLR7 in those CD20+ B cells in the pancreatic islets of individuals with type 1 diabetes is currently unknown, but, given that an elevated proportion of infiltrating B cells correlates with earlier diagnosis and more rapidly progressive disease [6], targeting of TLR7 could be of interest therapeutically.